# IDEAYA Biosciences Inc. (IDYA) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $39.86, market value $3.8 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). IDEAYA Biosciences Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 17.6×**. Each dollar of revenue is priced at 17.6×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 3.2×**. The shares trade at 3.2× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -3.0%** (5-yr avg -7.8%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -72.8%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -52.0%**. The company reported a net loss over the last twelve months.
- **Return on equity: -11.1%**. Return on equity is negative because earnings are negative.
- **Return on assets: -10.2%**. Each dollar of assets produces -10.2% of profit.

## Growth
- **Revenue growth (1 yr): 3024.4%** (3-yr 62.5%/yr, 5-yr 62.1%/yr). Revenue grew 3024.4% over the last year, against 62.1% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 61.9%**. Earnings per share rose 61.9%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 11.34** (quick 11.34). Current assets cover the next year's liabilities 11.34 times.
- **Altman Z-score: 28.38**. A Z-score of 28.38 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. IDEAYA Biosciences Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (13 analysts). 13 analysts cover IDEAYA Biosciences Inc.; the consensus is strong_buy, with an average price target of $52.15 (+31% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 54.3%** (YTD 15.3%, 3-mo 40.9%). The shares are up 54.3% over twelve months including dividends.
- **From 52-week high: -6.6%** (69.4% above the low). Trading 7% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 58**. An RSI of 58 is neutral.
- **Beta (1 yr): 1.02** (volatility 48%). Beta of 1.02 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=IDYA · Page: https://foliofundamentals.com/stocks/idya

Not investment advice.